Profiling antibodies provides deeper insights into a patient’s immune state, making it an essential tool for disease assessment and predicting treatment responses. As a key part of a multi-omics approach, antibody profiling—also known as immunoproteomics—complements genomics, transcriptomics, and proteomics.
Researchers are leveraging Sengenics protein microarrays to discover and validate antibody biomarkers for early disease detection, patient stratification, treatment monitoring, and predicting treatment outcomes, including immune-related adverse events (irAE).
Explore how our proprietary technology can elevate your research.
